Literature DB >> 19112174

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.

Rachel L Yamnik1, Alla Digilova, Daphne C Davis, Z Nilly Brodt, Christopher J Murphy, Marina K Holz.   

Abstract

The 40 S ribosomal S6 kinase 1 (S6K1) acts downstream of mTOR (mammalian target of rapamycin) and is sensitive to inhibition by rapamycin. The chromosomal region 17q23 containing the RPS6KB1 gene is frequently amplified in breast cancer cells, leading to S6K1 overexpression. The role of S6K1 in disease development and progression is supported by the observation that S6K1 overexpression is associated with poor prognosis in breast cancer patients. However, the identity of mammary cell-specific S6K1 targets is not well understood. In this study, we report that overexpression of S6K1 endows breast cancer cells with a proliferative advantage in low serum conditions and enhanced sensitivity to rapamycin. We investigate the molecular mechanism behind this observation to show that S6K1 regulates estrogen receptor alpha (ERalpha) by phosphorylating it on serine 167, leading to transcriptional activation of ERalpha. By contributing to the activation of ERalpha, S6K1 promotes ERalpha-mediated cell proliferation and may be a target of therapeutic intervention in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112174     DOI: 10.1074/jbc.M807532200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  90 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Authors:  Ana Bosch; Zhiqiang Li; Anna Bergamaschi; Haley Ellis; Eneda Toska; Aleix Prat; Jessica J Tao; Daniel E Spratt; Nerissa T Viola-Villegas; Pau Castel; Gerard Minuesa; Natasha Morse; Jordi Rodón; Yasir Ibrahim; Javier Cortes; Jose Perez-Garcia; Patricia Galvan; Judit Grueso; Marta Guzman; John A Katzenellenbogen; Michael Kharas; Jason S Lewis; Maura Dickler; Violeta Serra; Neal Rosen; Sarat Chandarlapaty; Maurizio Scaltriti; José Baselga
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 3.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 4.  Optimizing the use of neoadjuvant endocrine therapy.

Authors:  Laila S Agrawal; Ingrid A Mayer
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

5.  The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells.

Authors:  Anya Alayev; Sara Malka Berger; Melissa Y Kramer; Naomi S Schwartz; Marina K Holz
Journal:  J Cell Biochem       Date:  2015-03       Impact factor: 4.429

6.  Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.

Authors:  Kari L Ring; Melinda S Yates; Rosemarie Schmandt; Michaela Onstad; Qian Zhang; Joseph Celestino; Suet-Ying Kwan; Karen H Lu
Journal:  Int J Gynecol Cancer       Date:  2017-06       Impact factor: 3.437

7.  Estrogen induces RAD51C expression and localization to sites of DNA damage.

Authors:  Anya Alayev; Rachel S Salamon; Subrata Manna; Naomi S Schwartz; Adi Y Berman; Marina K Holz
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

8.  Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.

Authors:  Ben A Hall; Tae Yeon Kim; Maxwell N Skor; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2012-07-29       Impact factor: 4.872

9.  Genetic variants in the mTOR pathway and breast cancer risk in African American women.

Authors:  Ting-Yuan David Cheng; Christine B Ambrosone; Chi-Chen Hong; Kathryn L Lunetta; Song Liu; Qiang Hu; Song Yao; Lara Sucheston-Campbell; Elisa V Bandera; Edward A Ruiz-Narváez; Stephen Haddad; Melissa A Troester; Christopher A Haiman; Jeannette T Bensen; Andrew F Olshan; Julie R Palmer; Lynn Rosenberg
Journal:  Carcinogenesis       Date:  2015-11-16       Impact factor: 4.944

10.  Alternative splicing of S6K1 promotes non-small cell lung cancer survival.

Authors:  Hong Mei; Ye Wang; Jiquan Fan; Zhenyu Lin
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.